DUBLIN, April 6,
2022 /PRNewswire/ -- Theravance Biopharma, Inc.
(NASDAQ: TBPH) will present at the 21st Annual Needham
Virtual Healthcare Conference on Wednesday,
April 13, at 1:30 pm ET
(10:30 am PT/6:30 pm IST).
A webcast of the event may be accessed by visiting
Theravance.com, under the Investors section, Presentations and
Events. Replay of the webcast will be archived on the Company's
website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc. is a biopharmaceutical company
primarily focused on the discovery, development and
commercialization of respiratory medicines. Its core purpose is to
create medicines that help improve the lives of patients suffering
from respiratory illness.
In pursuit of its purpose, Theravance Biopharma leverages
decades of respiratory expertise to discover and develop
transformational medicines that make a difference. These efforts
have led to the development of FDA-approved
YUPELRI® (revefenacin) inhalation solution
indicated for the maintenance treatment of patients with chronic
obstructive pulmonary disease (COPD). Its respiratory pipeline of
internally discovered programs is targeted to address significant
patient respiratory needs.
Theravance Biopharma has an economic interest in potential
future payments from Glaxo Group Limited or one of its
affiliates (GSK) pursuant to its agreements with Innoviva, Inc.
relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE®, and
the Cross/Star logo are registered trademarks of
the Theravance Biopharma group of companies (in
the US and certain other countries).
YUPELRI® is a registered trademark of Mylan
Specialty L.P., a Viatris Company. Trademarks, trade names or
service marks of other companies appearing on this press release
are the property of their respective owners.
Contact Information:
Contact: Gail B. Cohen
Corporate Communications / 917-214-6603
View original content to download
multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-301518624.html
SOURCE Theravance Biopharma, Inc.